PROKPROKIDNEY CORP.

Nasdaq prokidney.com


$ 2.33 $ -0.04 (-1.69 %)    

Friday, 06-Sep-2024 15:59:56 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 2.33
$ 2.32 x 100
$ 2.34 x 645
-- - --
$ 1.12 - $ 8.56
400,844
na
674.94M
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-21-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-28-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-23-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 b-of-a-securities-maintains-neutral-on-prokidney-lowers-price-target-to-3

B of A Securities analyst Jason Gerberry maintains ProKidney (NASDAQ:PROK) with a Neutral and lowers the price target from $...

 prokidney-decides-to-prioritize-proact-1-plans-to-discontinue-proact-2-which-was-focused-on-enrollment-outside-us-now-expects-current-cash-to-support-operating-plans-into-q1-2027

The Company believes rilparencel is eligible for initial FDA approval under an expedited approval pathway based upon successful...

 prokidney-q2-eps-016-beats-017-estimate-ended-the-second-quarter-with-4315m--in-cash-and-cash-equivalents

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by ...

 reported-earlier-prokidney-prices-upsized-130m-public-offering-of-53719009-class-a-ordinary-shares-at-242share-and-concurrent-registered-direct-offering

All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold...

 prokidney-corp-announces-125m-public-offering-and-concurrent-registered-direct-offering-of-class-a-ordinary-shares

30-Day Option For Underwriters To Purchase Up To An Additional 15%

 jefferies-maintains-buy-on-prokidney-lowers-price-target-to-6

Jefferies analyst Kelly Shi maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $15 to $6.

 prokidney-announces-operational-updates-and-progress-in-european-and-us-clinical-trials-for-ckd-therapy-rilparencel

ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chr...

 b-of-a-securities-maintains-neutral-on-prokidney-raises-price-target-to-4

B of A Securities analyst Jason Gerberry maintains ProKidney (NASDAQ:PROK) with a Neutral and raises the price target from $...

 prokidney-q1-eps-016-remains-flat-yoy-exits-quarter-with-cash--equivalents-worth-329m

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.25) by ...

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION